Gregory Bailey Acquires 25,503 Shares of Biohaven Ltd. (NYSE:BHVN) Stock

Biohaven Ltd. (NYSE:BHVN - Get Free Report) Director Gregory Bailey bought 25,503 shares of the company's stock in a transaction dated Wednesday, April 24th. The shares were acquired at an average price of $39.18 per share, for a total transaction of $999,207.54. Following the completion of the transaction, the director now directly owns 1,600,071 shares in the company, valued at $62,690,781.78. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Gregory Bailey also recently made the following trade(s):

• On Monday, April 22nd, Gregory Bailey bought 48,780 shares of Biohaven stock. The shares were acquired at an average price of $41.00 per share, for a total transaction of $1,999,980.00.

Biohaven Price Performance

Shares of BHVN stock traded down $0.18 during trading on Thursday, hitting $38.54. 1,845,494 shares of the stock traded hands, compared to its average volume of 1,257,963. The firm has a market capitalization of $3.40 billion, a P/E ratio of -6.81 and a beta of 1.18. The firm's fifty day moving average price is $51.32 and its 200-day moving average price is $41.79. Biohaven Ltd. has a 52-week low of $12.35 and a 52-week high of $62.21.

Biohaven (NYSE:BHVN - Get Free Report) last announced its earnings results on Thursday, February 29th. The company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.40). As a group, equities research analysts expect that Biohaven Ltd. will post -5.85 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. HC Wainwright lifted their price objective on Biohaven from $50.00 to $63.00 and gave the stock a "buy" rating in a report on Monday, March 4th. UBS Group lifted their price objective on Biohaven from $59.00 to $60.00 and gave the stock a "buy" rating in a report on Tuesday. TD Cowen lifted their price objective on Biohaven from $35.00 to $55.00 and gave the stock an "outperform" rating in a report on Friday, March 1st. Royal Bank of Canada reissued an "outperform" rating and issued a $61.00 target price on shares of Biohaven in a research note on Tuesday, April 9th. Finally, JPMorgan Chase & Co. raised their target price on shares of Biohaven from $32.00 to $56.00 and gave the stock an "overweight" rating in a research note on Friday, February 23rd. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $52.13.

Institutional Trading of Biohaven

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BHVN. Thompson Davis & CO. Inc. purchased a new stake in Biohaven in the fourth quarter valued at approximately $214,000. Prevail Innovative Wealth Advisors LLC acquired a new position in shares of Biohaven in the fourth quarter worth $230,000. Private Advisor Group LLC acquired a new position in shares of Biohaven in the fourth quarter worth $231,000. Capstone Investment Advisors LLC acquired a new position in shares of Biohaven in the fourth quarter worth $235,000. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Biohaven in the third quarter worth $236,000. Hedge funds and other institutional investors own 88.78% of the company's stock.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.